Immunicom expects streamlined regulatory approval for the Immunopheresis therapy under the expertise of Dr. Shenouda alongside Immunicom's three ongoing clinical oncology trials.
The addition of Dr. Shenouda to the Immunicom team strengthens plans to advance FDA regulatory interaction culminating in approval for Immunopheresis therapies currently under evaluation in clinical trials for various malignancies.
Dr. Shenouda joins Immunicom from the Food and Drug Administration where he worked in both The Center for Drug Evaluation and Research and The Center for Devices and Radiological Health.
He previously worked at the National Institutes of Health conducting clinical trials and developing clinical trial portfolios to advance translational research.
He has worked as a clinician, researcher, and regulator, but has always focused on improving the lives of patients whether it be through direct patient care, clinical trial conduct, or evaluation of drug/device applications for the broad public health.
With deep knowledge of FDA regulations, Dr. Shenouda is known as an industry-leader in clinical trial designs, regulating medical devices, and has experience in bringing novel products to market.
He provides regulatory strategy based on his experience of countless devices with various risk profiles, from over-the-counter products to highly invasive, first in-human products.
In conjunction with work in device evaluation at the FDA, he has worked in the Office of Compliance to evaluate Good Clinical Practice conduct and brings regulatory and inspectional insights to the conduct of drug and device clinical trials.
Dr. Shenouda is a dual board-certified physician with a specialization in neurorehabilitation and completed his fellowship at the University of Washington and residency/chief residency at Baylor College of Medicine in Houston, Texas.
Immunicom creates novel immunotherapies designed to treat a variety of diseases using its Immunopheresis technology platform.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886